Emc Piaseczno Sp. z o.o.

Research site

Poland Ul. Mickiewicza 39, 05-500 Piaseczno, Poland

3 trials recruiting
Arteriosclerosis · Chronic inflammatory demyelinating polyradiculoneuropathy · Chronic kidney disease
Adult patients

About Specializations

Emc Piaseczno Sp. z o.o. in Piaseczno, Poland specialises in clinical trials of conditions such as Arteriosclerosis, Chronic inflammatory demyelinating polyradiculoneuropathy, Chronic kidney disease, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Endocrinology and Metabolic Disorders

The medical center is at the forefront of research in Endocrinology, with a particular focus on Type 2 Diabetes Mellitus (T2DM). The center's research aims to enhance the understanding and treatment of metabolic disorders, providing innovative solutions for patients with complex glycemic control issues.

Combination Therapy for T2DM
Glycemic Control Strategies
Metabolic Health Innovations

Through its pioneering studies, the center is contributing significantly to the development of advanced therapeutic approaches, such as the co-administration of pioglitazone with existing treatments, to improve patient outcomes in T2DM.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Mickiewicza 3905-500 PiasecznoPoland

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 7

More sites in Piaseczno Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:AZD6793
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Degarelix
Sponsor:Debiopharm International S.A.

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

Registered drug

Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Empagliflozin
Sponsor:Celltrion Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites